HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance. The DTG RESIST study combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet HIV Ročník 10; číslo 11; s. e733
Hlavní autoři:	Loosli, Tom, Hossmann, Stefanie, Ingle, Suzanne M, Okhai, Hajra, Kusejko, Katharina, Mouton, Johannes, Bellecave, Pantxika, van Sighem, Ard, Stecher, Melanie, d'Arminio Monforte, Antonella, Gill, M John, Sabin, Caroline A, Maartens, Gary, Günthard, Huldrych F, Sterne, Jonathan A C, Lessells, Richard, Egger, Matthias, Kouyos, Roger D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands 01.11.2023
Témata:	Cohort Studies Drug Resistance, Viral - genetics Heterocyclic Compounds, 3-Ring - pharmacology Heterocyclic Compounds, 3-Ring - therapeutic use HIV Infections - drug therapy HIV Integrase Inhibitors - pharmacology HIV Integrase Inhibitors - therapeutic use HIV Seropositivity - drug therapy HIV-1 - genetics Humans Lamivudine - therapeutic use Reverse Transcriptase Inhibitors - therapeutic use
ISSN:	2352-3018, 2352-3018
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance. The DTG RESIST study combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for dolutegravir resistance. We included cohorts with INSTI resistance data from two collaborations (ART Cohort Collaboration, International epidemiology Databases to Evaluate AIDS in Southern Africa), and the UK Collaborative HIV Cohort. Eight cohorts from Canada, France, Germany, Italy, the Netherlands, Switzerland, South Africa, and the UK contributed data on individuals who were viraemic on dolutegravir-based ART and underwent genotypic resistance testing. Individuals with unknown dolutegravir initiation date were excluded. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models. We included 599 people with genotypic resistance testing on dolutegravir-based ART between May 22, 2013, and Dec 20, 2021. Most had HIV-1 subtype B (n=351, 59%), a third had been exposed to first-generation INSTIs (n=193, 32%), 70 (12%) were on dolutegravir dual therapy, and 18 (3%) were on dolutegravir monotherapy. INSTI DRMs were detected in 86 (14%) individuals; 20 (3%) had more than one mutation. Most (n=563, 94%) were susceptible to dolutegravir, seven (1%) had potential low, six (1%) low, 17 (3%) intermediate, and six (1%) high-level dolutegravir resistance. The risk of dolutegravir resistance was higher on dolutegravir monotherapy (adjusted odds ratio [aOR] 34·1, 95% CI 9·93-117) and dolutegravir plus lamivudine dual therapy (aOR 9·21, 2·20-38·6) compared with combination ART, and in the presence of potential low or low (aOR 5·23, 1·32-20·7) or intermediate or high-level (aOR 13·4, 4·55-39·7) nucleoside reverse transcriptase inhibitor (NRTI) resistance. Among people with viraemia on dolutegravir-based ART, INSTI DRMs and dolutegravir resistance were rare. NRTI resistance substantially increased the risk of dolutegravir resistance, which is of concern, notably in resource-limited settings. Monitoring is important to prevent resistance at the individual and population level and ensure the long-term sustainability of ART. US National Institutes of Health, Swiss National Science Foundation.
AbstractList	The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance. The DTG RESIST study combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for dolutegravir resistance.BACKGROUNDThe widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance. The DTG RESIST study combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for dolutegravir resistance.We included cohorts with INSTI resistance data from two collaborations (ART Cohort Collaboration, International epidemiology Databases to Evaluate AIDS in Southern Africa), and the UK Collaborative HIV Cohort. Eight cohorts from Canada, France, Germany, Italy, the Netherlands, Switzerland, South Africa, and the UK contributed data on individuals who were viraemic on dolutegravir-based ART and underwent genotypic resistance testing. Individuals with unknown dolutegravir initiation date were excluded. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models.METHODSWe included cohorts with INSTI resistance data from two collaborations (ART Cohort Collaboration, International epidemiology Databases to Evaluate AIDS in Southern Africa), and the UK Collaborative HIV Cohort. Eight cohorts from Canada, France, Germany, Italy, the Netherlands, Switzerland, South Africa, and the UK contributed data on individuals who were viraemic on dolutegravir-based ART and underwent genotypic resistance testing. Individuals with unknown dolutegravir initiation date were excluded. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models.We included 599 people with genotypic resistance testing on dolutegravir-based ART between May 22, 2013, and Dec 20, 2021. Most had HIV-1 subtype B (n=351, 59%), a third had been exposed to first-generation INSTIs (n=193, 32%), 70 (12%) were on dolutegravir dual therapy, and 18 (3%) were on dolutegravir monotherapy. INSTI DRMs were detected in 86 (14%) individuals; 20 (3%) had more than one mutation. Most (n=563, 94%) were susceptible to dolutegravir, seven (1%) had potential low, six (1%) low, 17 (3%) intermediate, and six (1%) high-level dolutegravir resistance. The risk of dolutegravir resistance was higher on dolutegravir monotherapy (adjusted odds ratio [aOR] 34·1, 95% CI 9·93-117) and dolutegravir plus lamivudine dual therapy (aOR 9·21, 2·20-38·6) compared with combination ART, and in the presence of potential low or low (aOR 5·23, 1·32-20·7) or intermediate or high-level (aOR 13·4, 4·55-39·7) nucleoside reverse transcriptase inhibitor (NRTI) resistance.FINDINGSWe included 599 people with genotypic resistance testing on dolutegravir-based ART between May 22, 2013, and Dec 20, 2021. Most had HIV-1 subtype B (n=351, 59%), a third had been exposed to first-generation INSTIs (n=193, 32%), 70 (12%) were on dolutegravir dual therapy, and 18 (3%) were on dolutegravir monotherapy. INSTI DRMs were detected in 86 (14%) individuals; 20 (3%) had more than one mutation. Most (n=563, 94%) were susceptible to dolutegravir, seven (1%) had potential low, six (1%) low, 17 (3%) intermediate, and six (1%) high-level dolutegravir resistance. The risk of dolutegravir resistance was higher on dolutegravir monotherapy (adjusted odds ratio [aOR] 34·1, 95% CI 9·93-117) and dolutegravir plus lamivudine dual therapy (aOR 9·21, 2·20-38·6) compared with combination ART, and in the presence of potential low or low (aOR 5·23, 1·32-20·7) or intermediate or high-level (aOR 13·4, 4·55-39·7) nucleoside reverse transcriptase inhibitor (NRTI) resistance.Among people with viraemia on dolutegravir-based ART, INSTI DRMs and dolutegravir resistance were rare. NRTI resistance substantially increased the risk of dolutegravir resistance, which is of concern, notably in resource-limited settings. Monitoring is important to prevent resistance at the individual and population level and ensure the long-term sustainability of ART.INTERPRETATIONAmong people with viraemia on dolutegravir-based ART, INSTI DRMs and dolutegravir resistance were rare. NRTI resistance substantially increased the risk of dolutegravir resistance, which is of concern, notably in resource-limited settings. Monitoring is important to prevent resistance at the individual and population level and ensure the long-term sustainability of ART.US National Institutes of Health, Swiss National Science Foundation.FUNDINGUS National Institutes of Health, Swiss National Science Foundation. The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance. The DTG RESIST study combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for dolutegravir resistance. We included cohorts with INSTI resistance data from two collaborations (ART Cohort Collaboration, International epidemiology Databases to Evaluate AIDS in Southern Africa), and the UK Collaborative HIV Cohort. Eight cohorts from Canada, France, Germany, Italy, the Netherlands, Switzerland, South Africa, and the UK contributed data on individuals who were viraemic on dolutegravir-based ART and underwent genotypic resistance testing. Individuals with unknown dolutegravir initiation date were excluded. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models. We included 599 people with genotypic resistance testing on dolutegravir-based ART between May 22, 2013, and Dec 20, 2021. Most had HIV-1 subtype B (n=351, 59%), a third had been exposed to first-generation INSTIs (n=193, 32%), 70 (12%) were on dolutegravir dual therapy, and 18 (3%) were on dolutegravir monotherapy. INSTI DRMs were detected in 86 (14%) individuals; 20 (3%) had more than one mutation. Most (n=563, 94%) were susceptible to dolutegravir, seven (1%) had potential low, six (1%) low, 17 (3%) intermediate, and six (1%) high-level dolutegravir resistance. The risk of dolutegravir resistance was higher on dolutegravir monotherapy (adjusted odds ratio [aOR] 34·1, 95% CI 9·93-117) and dolutegravir plus lamivudine dual therapy (aOR 9·21, 2·20-38·6) compared with combination ART, and in the presence of potential low or low (aOR 5·23, 1·32-20·7) or intermediate or high-level (aOR 13·4, 4·55-39·7) nucleoside reverse transcriptase inhibitor (NRTI) resistance. Among people with viraemia on dolutegravir-based ART, INSTI DRMs and dolutegravir resistance were rare. NRTI resistance substantially increased the risk of dolutegravir resistance, which is of concern, notably in resource-limited settings. Monitoring is important to prevent resistance at the individual and population level and ensure the long-term sustainability of ART. US National Institutes of Health, Swiss National Science Foundation.
Author	Loosli, Tom Hossmann, Stefanie Okhai, Hajra d'Arminio Monforte, Antonella Maartens, Gary Egger, Matthias Mouton, Johannes van Sighem, Ard Günthard, Huldrych F Kouyos, Roger D Gill, M John Sterne, Jonathan A C Stecher, Melanie Kusejko, Katharina Ingle, Suzanne M Sabin, Caroline A Lessells, Richard Bellecave, Pantxika
Author_xml	– sequence: 1 givenname: Tom surname: Loosli fullname: Loosli, Tom organization: Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland – sequence: 2 givenname: Stefanie surname: Hossmann fullname: Hossmann, Stefanie organization: Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland – sequence: 3 givenname: Suzanne M surname: Ingle fullname: Ingle, Suzanne M organization: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK – sequence: 4 givenname: Hajra surname: Okhai fullname: Okhai, Hajra organization: Institute for Global Health, University College London, London, UK – sequence: 5 givenname: Katharina surname: Kusejko fullname: Kusejko, Katharina organization: Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland – sequence: 6 givenname: Johannes surname: Mouton fullname: Mouton, Johannes organization: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa – sequence: 7 givenname: Pantxika surname: Bellecave fullname: Bellecave, Pantxika organization: Virology Laboratory, University Hospital Bordeaux, Bordeaux, France – sequence: 8 givenname: Ard surname: van Sighem fullname: van Sighem, Ard organization: Stichting HIV Monitoring, Amsterdam, Netherlands – sequence: 9 givenname: Melanie surname: Stecher fullname: Stecher, Melanie organization: German Center for Infection Research (DZIF), Partner-Site Cologne-Bonn, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany – sequence: 10 givenname: Antonella surname: d'Arminio Monforte fullname: d'Arminio Monforte, Antonella organization: Italian Cohort Naive Antiretrovirals (ICONA), University of Milan, Milan, Italy – sequence: 11 givenname: M John surname: Gill fullname: Gill, M John organization: Southern Alberta Clinic, Calgary, AB, Canada; Department of Medicine, University of Calgary, Calgary, AB, Canada – sequence: 12 givenname: Caroline A surname: Sabin fullname: Sabin, Caroline A organization: Institute for Global Health, University College London, London, UK – sequence: 13 givenname: Gary surname: Maartens fullname: Maartens, Gary organization: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa – sequence: 14 givenname: Huldrych F surname: Günthard fullname: Günthard, Huldrych F organization: Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland – sequence: 15 givenname: Jonathan A C surname: Sterne fullname: Sterne, Jonathan A C organization: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK – sequence: 16 givenname: Richard surname: Lessells fullname: Lessells, Richard organization: KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa – sequence: 17 givenname: Matthias surname: Egger fullname: Egger, Matthias email: matthias.egger@unibe.ch organization: Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Electronic address: matthias.egger@unibe.ch – sequence: 18 givenname: Roger D surname: Kouyos fullname: Kouyos, Roger D organization: Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/37832567$$D View this record in MEDLINE/PubMed
BookMark	eNpNkF9LwzAUxYNM3Jz7CEoe50M1SZsm9U2GusHAB__gW7lNb7dK19QkHezbW3CKT-eew4_D5ZyTUWtbJOSSsxvOeHr7ImIpophxPRfxNWNC6OjjhEz-4tG_e0xm3n8yxrhMtEzEGRnHSsdCpmpCdsvVe8Rp6foNdehrH6A1SOuWdmi7BqltaWmbPuDGwb52UQEeSwptqB0GZ4cIGhq26KA73FGgxjYNFNZBqPc4uK11YcChOQzlF-S0gsbj7KhT8vb48LpYRuvnp9Xifh0ZKXiICmFSTCWkJaQKq0yrKmMYVxWYKjMMksIwlhimGRcFT0spmSmyxIBKEtQKxJTMf3o7Z7969CHf1d7g8FmLtve50ErFWmSJHNCrI9oXOyzzztU7cIf8dyLxDXH_bfc
CitedBy_id	crossref_primary_10_1093_cid_ciae278 crossref_primary_10_1093_jac_dkaf180 crossref_primary_10_1093_cid_ciaf204 crossref_primary_10_1097_QAD_0000000000004202 crossref_primary_10_1016_S2352_3018_25_00068_2 crossref_primary_10_1093_ofid_ofae321 crossref_primary_10_1093_ofid_ofaf530 crossref_primary_10_1097_QAD_0000000000004007 crossref_primary_10_1093_cid_ciaf481 crossref_primary_10_3390_v15122426 crossref_primary_10_3390_microorganisms13020321 crossref_primary_10_1093_jac_dkaf019 crossref_primary_10_1016_S2352_3018_25_00164_X crossref_primary_10_1097_COH_0000000000000876 crossref_primary_10_1016_S2214_109X_25_00104_4 crossref_primary_10_1097_QAD_0000000000004081 crossref_primary_10_1093_jac_dkae164 crossref_primary_10_1016_j_jbc_2025_108319 crossref_primary_10_3390_v16071162 crossref_primary_10_1093_jac_dkae086 crossref_primary_10_1097_MNH_0000000000001018 crossref_primary_10_1097_QAI_0000000000003657 crossref_primary_10_1038_s41467_024_47254_z crossref_primary_10_1097_QAD_0000000000004099 crossref_primary_10_3390_v16091465 crossref_primary_10_1093_ofid_ofae198 crossref_primary_10_1016_S2352_3018_23_00329_6 crossref_primary_10_1097_QAD_0000000000004138 crossref_primary_10_1093_cid_ciae185 crossref_primary_10_3390_v16101634 crossref_primary_10_1038_s43856_025_00875_x crossref_primary_10_1093_cid_ciaf471 crossref_primary_10_1093_cid_ciae261 crossref_primary_10_1093_ofid_ofaf526 crossref_primary_10_1136_bmjopen_2024_085819 crossref_primary_10_1007_s40265_025_02181_1 crossref_primary_10_3389_fimmu_2025_1670423 crossref_primary_10_1016_S2352_3018_25_00127_4 crossref_primary_10_1093_jac_dkae472 crossref_primary_10_1038_s41591_023_02763_0 crossref_primary_10_36303_SAPJ_0135 crossref_primary_10_1093_cid_ciaf346 crossref_primary_10_1093_cid_ciae016 crossref_primary_10_1016_j_jve_2025_100608 crossref_primary_10_3390_v17050699 crossref_primary_10_1093_ofid_ofae468 crossref_primary_10_3390_pathogens14010048 crossref_primary_10_3390_v17081129 crossref_primary_10_1001_jama_2024_24543 crossref_primary_10_3389_fpubh_2025_1667417 crossref_primary_10_1016_S2352_3018_24_00060_2 crossref_primary_10_1097_QAI_0000000000003676 crossref_primary_10_1093_cid_ciad757 crossref_primary_10_1177_03000605241301883 crossref_primary_10_4102_sajhivmed_v26i1_1677 crossref_primary_10_1186_s12981_025_00787_9 crossref_primary_10_1080_09540121_2025_2474672 crossref_primary_10_1093_cid_ciae127 crossref_primary_10_3390_v16091484 crossref_primary_10_1016_j_ijbiomac_2025_145195 crossref_primary_10_1093_cid_ciaf135 crossref_primary_10_1016_S2214_109X_24_00553_9 crossref_primary_10_1016_j_bjid_2025_104513 crossref_primary_10_1089_aid_2023_0068 crossref_primary_10_1093_ofid_ofaf305 crossref_primary_10_1186_s13072_024_00564_4 crossref_primary_10_4102_sajhivmed_v25i1_1567 crossref_primary_10_1016_j_jmii_2024_11_003 crossref_primary_10_1016_S2352_3018_23_00259_X crossref_primary_10_1371_journal_pone_0320623 crossref_primary_10_1093_jac_dkae377 crossref_primary_10_1371_journal_pmed_1004720 crossref_primary_10_1186_s12981_025_00708_w
ContentType	Journal Article
Copyright	Copyright © 2023 Elsevier Ltd. All rights reserved.
Copyright_xml	– notice: Copyright © 2023 Elsevier Ltd. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/S2352-3018(23)00228-X
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Biology
EISSN	2352-3018
ExternalDocumentID	37832567
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation	US National Institutes of Health, Swiss National Science Foundation.
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: R01 AI152772 – fundername: NIAAA NIH HHS grantid: U01 AA026209 – fundername: NIAID NIH HHS grantid: U01 AI069924 – fundername: NIAID NIH HHS grantid: R01 AI167699
GroupedDBID	-RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AGCQF AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CGR CUY CVF EBS ECM EFKBS EIF EJD FDB HZ~ M41 NPM O9- OD- OO. ROL Z5R 7X8
ID	FETCH-LOGICAL-c521t-b2c6e65a6da67ef987f90e3ffacf9c0a4bc004c08012b16d550cb94ca744e87a2
IEDL.DBID	7X8
ISICitedReferencesCount	89
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001108961600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2352-3018
IngestDate	Sun Sep 28 00:19:55 EDT 2025 Mon Jul 21 05:52:51 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11
Language	English
License	Copyright © 2023 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c521t-b2c6e65a6da67ef987f90e3ffacf9c0a4bc004c08012b16d550cb94ca744e87a2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	http://www.thelancet.com/article/S235230182300228X/pdf
PMID	37832567
PQID	2877382945
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2877382945 pubmed_primary_37832567
PublicationCentury	2000
PublicationDate	2023-11-01
PublicationDateYYYYMMDD	2023-11-01
PublicationDate_xml	– month: 11 year: 2023 text: 2023-11-01 day: 01
PublicationDecade	2020
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	The lancet HIV
PublicationTitleAlternate	Lancet HIV
PublicationYear	2023
References	37066200 - medRxiv. 2023 Apr 05:2023.04.05.23288183. doi: 10.1101/2023.04.05.23288183 37832568 - Lancet HIV. 2023 Nov;10(11):e696-e698. doi: 10.1016/S2352-3018(23)00259-X
References_xml	– reference: 37832568 - Lancet HIV. 2023 Nov;10(11):e696-e698. doi: 10.1016/S2352-3018(23)00259-X – reference: 37066200 - medRxiv. 2023 Apr 05:2023.04.05.23288183. doi: 10.1101/2023.04.05.23288183
SSID	ssj0001548542
Score	2.5555222
Snippet	The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	e733
SubjectTerms	Cohort Studies Drug Resistance, Viral - genetics Heterocyclic Compounds, 3-Ring - pharmacology Heterocyclic Compounds, 3-Ring - therapeutic use HIV Infections - drug therapy HIV Integrase Inhibitors - pharmacology HIV Integrase Inhibitors - therapeutic use HIV Seropositivity - drug therapy HIV-1 - genetics Humans Lamivudine - therapeutic use Reverse Transcriptase Inhibitors - therapeutic use
Title	HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis
URI	https://www.ncbi.nlm.nih.gov/pubmed/37832567 https://www.proquest.com/docview/2877382945
Volume	10
WOSCitedRecordID	wos001108961600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwGA3qKHhxX8aNCB70EGzTrF5ERFHQQXBhbkO2yhzsaGcc8N_7pa2OF0Hw0kNpS0levrx8yfceQgeZVVmeq5xw4RPCBDXE5jYhyrLEah-CquQYnm5kp6O6XX3XJNyGzbHKr5hYBWo_cDFHfgzMXmaKasZPX99IdI2Ku6uNhcY0amVAZSKqZVdNcixAx3nln0OBZxDAspoU8Rzff988pNlRJQRDur8TzWrCuVz8768uoYWGauKzGhvLaCoUK2iuNp_8WEUvV9dPJMW-fH_GsOaOPBIAgPsFrk-V40GBfQRmlJMY90sSJzyPoScgSo5iJqKEr9f1Wx8n2OAfkBoHHJ13yxE8XouerKHHy4uH8yvSmC8QFz0OiKVOBMGN8EbIkGslc50E6Ffjcu0Sw6yD8RV1ylNqU-FhpeOsZs5IxoKShq6jmWJQhE2EtZU8dS7wVHmmbdCcU-WdSgQFAmNZG-1_tWMPwB13LEwRBu_D3qQl22ij7ozea63C0cskBCMu5NYf3t5G89Emvq4h3EGtHIZ22EWzbjzqD8u9CjVw7dzdfgKGp80C
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV-1+drug+resistance+in+people+on+dolutegravir-based+antiretroviral+therapy%3A+a+collaborative+cohort+analysis&rft.jtitle=The+lancet+HIV&rft.au=Loosli%2C+Tom&rft.au=Hossmann%2C+Stefanie&rft.au=Ingle%2C+Suzanne+M&rft.au=Okhai%2C+Hajra&rft.date=2023-11-01&rft.eissn=2352-3018&rft.volume=10&rft.issue=11&rft.spage=e733&rft_id=info:doi/10.1016%2FS2352-3018%2823%2900228-X&rft_id=info%3Apmid%2F37832567&rft_id=info%3Apmid%2F37832567&rft.externalDocID=37832567
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3018&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3018&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3018&client=summon